KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Revenue: 2009-2025

Historic Revenue for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Sep 2025 value amounting to $69.5 million.

  • Rigel Pharmaceuticals' Revenue rose 25.59% to $69.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.1 million, marking a year-over-year increase of 79.13%. This contributed to the annual value of $179.3 million for FY2024, which is 53.38% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Revenue is $69.5 million, which was down 31.69% from $101.7 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Revenue peaked at $101.7 million during Q2 2025, and registered a low of $16.7 million during Q1 2022.
  • Moreover, its 3-year median value for Revenue was $36.8 million (2024), whereas its average is $47.3 million.
  • In the last 5 years, Rigel Pharmaceuticals' Revenue tumbled by 79.34% in 2022 and then skyrocketed by 176.01% in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Revenue stood at $20.4 million in 2021, then skyrocketed by 151.25% to $51.3 million in 2022, then crashed by 30.20% to $35.8 million in 2023, then spiked by 60.92% to $57.6 million in 2024, then rose by 25.59% to $69.5 million in 2025.
  • Its Revenue stands at $69.5 million for Q3 2025, versus $101.7 million for Q2 2025 and $53.3 million for Q1 2025.